Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 1998

View Archived Issues

Atrix acquires ViroTex and expands drug delivery technology base

Ascent to terminate copromotion agreement with Bristol-Myers Squibb

Maxia initiates pivotal phase III trial with MX-6 for treatment of CIN

Sixty new products in the forecasted Aventis pipeline

Bracco announces approval and launch of second-generation MRI contrast agent

LXR initiates preclinical development of second-generation analogue of Elirex

Optimum compound from COX-2 inhibitor series identified by Merck Frosst

Heterocyclic melatonergic agents designed at ADIR

New SERMS from Lilly

Astra patents new pyrazolopyrimidinedione immunosuppressants

Shionogi reports synthesis and initial pharmacological testing of new NPY antagonists

Potent anti-MRSA agents developed by Sankyo

FDA approves Verelan PM; launch scheduled for early 1999

Pharming and Gem to codevelop human lactoferrin (GPX-400) to neutralize heparin

FDA approves Hycamtin as second-line treatment of small cell lung cancer

First results from infant trial indicate utility of cetirizine for preventing development of asthma

SB files for E.U. approval of Avandia for treatment of type II diabetes

MDX-210 demonstrates antitumor activity in phase II studies

Six-month treatment with ciprofloxacin improves response rate in ulcerative colitis

Enrollment completed in phase I Biomira lung cancer vaccine trial

Centocor will market Retavase exclusively in the U.S. starting in January

Coulter and SB enter agreement to develop and commercialize I-131 anti-B1 antibody

Canadian approval obtained for Serostim

Zomig copromoted by Cephalon in the U.K.

Maxamine Therapy enters phase II trial for late-stage RCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...